Rein Therapeutics, Inc RNTX 深 滬
等待開盤 07-22 09:30:00 美东时间
0.8948
+0.051
+6.02%
華盛通- 最 高0.9321
- 今 開0.85
- 成交量 59.14万股
- 最 低 0.8299
- 昨 收 0.844
- 總市值 7654.03万
- 52周最高 2.18
- 市盈率 靜 --
- 換手率 0.69%
- 52周最低 0.8299
- 委 比 81.82%
- 總股本 8553.90万
- 歷史最高 309.60
- 量 比 1.87
- 振 幅 12.11%
- 歷史最低 0.8299
- 每 手 1
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
Maxim Group Initiates Coverage On Rein Therapeutics with Buy Rating, Announces Price Target of $4
Maxim Group analyst Jason McCarthy initiates coverage on Rein Therapeutics (NASDAQ:RNTX) with a Buy rating and announces Price Target of $4.
07-21 02:13
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8
HC Wainwright & Co. analyst Brandon Folkes maintains Rein Therapeutics (NASDAQ:RNTX) with a Buy and lowers the price target from $10 to $8.
06-01 18:42
Rein Therapeutics Q1 EPS $(0.19) Beats $(0.49) Estimate
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.49) by 61.22 percent. This is a 24 percent increase over losses of $(0.25) per share from
05-15 21:27
Why Twilio Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates, causing shares to jump 20.6% in pre-market trading. Other gainers include CUE, SST, AKAN, XXII, SDOT, TEAM, ISPC, and FIVN, while BAFN, RBLX, SKBL, and RNTX were among the losers.
05-01 16:36
Rein Therapeutics Enrolled 8 Patients In RENEW Trial
8 patients enrolled, with additional patients expected in the near termEnrollment initiated in March 2026, with patients being added on a regular basisClinical trial sites active in the United States, Australia,
04-29 20:02
Rein Therapeutics Files Prospectus For 30M Share Offering At ~$1.66/Share
REIN THERAPEUTICS, INC.30,000,000 Shares of Common StockWe are selling 30,000,000 shares of our common stock at an assumed public offering price of $1.66 per share, the last reported sale price of our common stock
04-29 05:35
Rein Therapeutics Q4 Adj. EPS $(0.11) Beats $(0.24) Estimate
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.24) by 54.17 percent. This is a 94.18 percent increase over losses of $(1.89) per share from
03-27 05:55
Brookline Capital Downgrades Rein Therapeutics to Hold
Brookline Capital analyst Kemp Dolliver downgrades Rein Therapeutics (NASDAQ:RNTX) from Buy to Hold.
01-22 00:03
